Polyarticular juvenile idiopathic arthritis
ICD-10 M08 · ICD-11 FA24.1

Polyarticular Juvenile Idiopathic Arthritis: When the First Biologic Plus DMARD Regimen Fails to Reach Low Disease Activity

Clinical Scenario

This protocol applies to children with juvenile idiopathic arthritis (JIA) — non-systemic polyarthritis with five or more joints ever involved — with onset before age 16. Systemic arthritis and sacroiliitis are excluded from this population.

Previous Treatment — Failure Condition

The prior treatment step added a biologic agent in combination with a DMARD. Escalation to this next protocol is indicated when that regimen did not achieve low disease activity (cJADAS-10 ≤2.5) — the defined threshold for an adequate treatment response.

Next-Step Approach

After failure of a first TNFi-based biologic regimen, this protocol addresses switching to an alternative biologic category — with specific clinical circumstances also informing whether a different route within the same class may be considered instead.

Target: Low disease activity (cJADAS-10 ≤2.5)
Instant Access to Structured Evidence-Based Regimens
References
DOI: 10.1002/acr.23870
The term juvenile idiopathic arthritis (JIA) defines a heterogeneous collection of inflammatory arthritides of unknown etiology with onset prior to age 16 years and a minimum duration of 6 weeks, following the exclusion of other known causes of synovitis.
This group includes children with JIA and polyarthritis (≥5 joints ever involved) and may include children from different ILAR JIA categories but excludes children with systemic arthritis or sacroiliitis.
In patients with JIA and polyarthritis and moderate or high disease activity receiving a first TNFi (with or without DMARD), switching to a non-TNFi biologic (tocilizumab or abatacept) is conditionally recommended over switching to a second TNFi.
The Voting Panel agreed that a second TNFi may be appropriate for patients who had a good initial response to their first TNFi (i.e., secondary failure), particularly failure due to the presence of suspected or measured antidrug antibodies to the first TNFi.
View source ↗